For traders
For futures traders: know the catalysts before the open
S&P 500, Nasdaq, Dow, Russell, crude, gold and Treasury futures move on scheduled data and the Fed. The Chronicle gives you the calendar, the levels and what each release tends to do.
The week ahead, every Sunday
Levels, the data calendar and the catalysts for index, energy, metals and rates futures, published before the week starts.
A trader's guide to every release
CPI, payrolls, jobless claims, PMIs, GDP and Fed decisions, each with what markets tend to do on a hot or cool surprise.
Round-the-clock prices
Live 24-hour index, crude, gold and T-note prices that track the futures markets overnight.
Rates coverage
Treasury yields from the U.S. Treasury's own data, Fed decisions and projections, the drivers behind rate-sensitive contracts.
Right now
Market data by TradingView and Coinbase. Rates are the latest daily or weekly Federal Reserve data. Futures boards show 24-hour index and commodity prices that track futures markets. Some quotes may be delayed. Not investment advice.
Latest from the desk
Hassett asks why the Fed is hiking with core inflation at 2%; that 2% leans on a flat June
The White House economic adviser questioned last week's rate rise and criticized officials calling for more. Government data show core prices ran at about a 3% pace in July and August, and the two-year yield jumped to 4.85%.
FDA advisers back Grail's Galleri cancer blood test 7-2, but split 6-4 on whether it works
The panel said the benefits outweigh the risks, a first for a multi-cancer blood test. In Grail's main study the test caught about one in three cancers diagnosed within a year, and the stock had already jumped 34% before the vote.
Starboard builds a stake in Knife River and pushes for a sale or higher margins; stock rises after hours
The activist wants the aggregates and paving company to close its margin gap with peers or explore a sale, the WSJ reported. Knife River's own numbers show why a single margin point is worth about $5 a share.
Arcturus calls its OTC deficiency data encouraging; the Phase 2 had seven evaluable patients and no placebo
ARCT-810 lowered average ammonia and glutamine in a small open-label study, but Arcturus is already moving a next-generation drug into the same trial. The stock was little changed after hours.
U.S. and China extend the Busan trade truce to Jan. 10, moving the tariff deadline past the holidays
Treasury Secretary Scott Bessent said the truce due to lapse on Nov. 10 will now run to Jan. 10. The two extra months carry the deal past the first full-year test of China's soybean pledge and past peak holiday shipping.
Smurfit Westrock buys CMPC's Chile box business for $420 million, below its own valuation multiple
The packaging giant is paying less than 6 times post-synergy EBITDA for a Santiago paper mill and three box plants. On our math its own shares trade at about 7.6 times this year's guided EBITDA.
The Company Chronicle publishes market information and news, not investment advice.